MSOR7 Presentation Time: 5:30 PM

IF 1.7 4区医学 Q4 ONCOLOGY

Brachytherapy Pub Date : 2024-10-25 DOI:10.1016/j.brachy.2024.08.041

Daya Nand Sharma MD, Surendra Kumar Saini MD, Vellaiyan Subramani PhD

{"title":"MSOR7 Presentation Time: 5:30 PM","authors":"Daya Nand Sharma MD, Surendra Kumar Saini MD, Vellaiyan Subramani PhD","doi":"10.1016/j.brachy.2024.08.041","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>High-dose-rate interstitial brachytherapy (HDR-IBT) is a favored treatment option over partial penectomy in patients with T1-T2 stage penile carcinoma due to its organ preservation capability. There are limited studies on HDR-IBT in the literature. We analyzed the data of patients of early-stage penile cancer treated with HDR-IBT alone at our center.</div></div><div><h3>Methods and Materials</h3><div>Between April 2010 and March 2019, 32 patients with T1-T2 stage penile carcinoma were treated with HDR-IBT at our center. Size of the primary lesion ranged from 1.5 cm to 4.0 cm. A free hand implant was performed using plastic catheters in 2-4 planes. The prescription dose of HDR-IBT was 42-51 Gy in 14-17 fractions (twice a day fractionation schedule). Patients were followed up regularly for assessment of local control, survival, toxicity and sexual function.</div></div><div><h3>Results</h3><div>At a median follow up of 52 months, 6 patients developed recurrent disease at loco-regional site. The 5-year overall survival (OS) was 81% with penis preservation rate (PPR) of 85%. Meatal stenosis was the commonest long-term complication observed in 16 patients. Fifteen of them were managed by frequent urethral dilatations and one patient required temporary suprapubic cystostomy. Eighteen patients had satisfactory sexual function status at the last follow up visit.</div></div><div><h3>Conclusions</h3><div>The long-term results of our study have demonstrated excellent local control rate and acceptable toxicity with HDR-IBT in patients with T1-2 stage penile carcinoma.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brachytherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1538472124001776","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

High-dose-rate interstitial brachytherapy (HDR-IBT) is a favored treatment option over partial penectomy in patients with T1-T2 stage penile carcinoma due to its organ preservation capability. There are limited studies on HDR-IBT in the literature. We analyzed the data of patients of early-stage penile cancer treated with HDR-IBT alone at our center.

Methods and Materials

Between April 2010 and March 2019, 32 patients with T1-T2 stage penile carcinoma were treated with HDR-IBT at our center. Size of the primary lesion ranged from 1.5 cm to 4.0 cm. A free hand implant was performed using plastic catheters in 2-4 planes. The prescription dose of HDR-IBT was 42-51 Gy in 14-17 fractions (twice a day fractionation schedule). Patients were followed up regularly for assessment of local control, survival, toxicity and sexual function.

Results

At a median follow up of 52 months, 6 patients developed recurrent disease at loco-regional site. The 5-year overall survival (OS) was 81% with penis preservation rate (PPR) of 85%. Meatal stenosis was the commonest long-term complication observed in 16 patients. Fifteen of them were managed by frequent urethral dilatations and one patient required temporary suprapubic cystostomy. Eighteen patients had satisfactory sexual function status at the last follow up visit.

Conclusions

The long-term results of our study have demonstrated excellent local control rate and acceptable toxicity with HDR-IBT in patients with T1-2 stage penile carcinoma.

查看原文本刊更多论文

MSOR7 演讲时间：下午 5:30

目的对于T1-T2期阴茎癌患者，高剂量率间质近距离放射治疗（HDR-IBT）因其保留器官的能力而比阴茎部分切除术更受青睐。有关 HDR-IBT 的文献研究有限。我们分析了本中心单独使用HDR-IBT治疗早期阴茎癌患者的数据。方法和材料2010年4月至2019年3月期间，本中心对32例T1-T2期阴茎癌患者进行了HDR-IBT治疗。原发病灶大小从1.5厘米到4.0厘米不等。使用塑料导管在2-4个平面内进行徒手植入。HDR-IBT的处方剂量为42-51 Gy，分14-17次进行（一天两次分次）。对患者进行定期随访，评估局部控制情况、生存率、毒性和性功能。结果中位随访52个月，6名患者在局部区域复发。5年总生存率（OS）为81%，阴茎保留率（PPR）为85%。16例患者中最常见的长期并发症是肛门狭窄。其中15名患者通过频繁的尿道扩张术进行了处理，1名患者需要进行临时耻骨上膀胱造口术。18名患者在最后一次随访时性功能状况令人满意。结论我们的研究结果表明，对T1-2期阴茎癌患者进行HDR-IBT治疗后，局部控制率极佳，毒性也可接受。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Brachytherapy 医学-核医学

CiteScore

3.40

自引率

21.10%

发文量

119

审稿时长

9.1 weeks

期刊介绍： Brachytherapy is an international and multidisciplinary journal that publishes original peer-reviewed articles and selected reviews on the techniques and clinical applications of interstitial and intracavitary radiation in the management of cancers. Laboratory and experimental research relevant to clinical practice is also included. Related disciplines include medical physics, medical oncology, and radiation oncology and radiology. Brachytherapy publishes technical advances, original articles, reviews, and point/counterpoint on controversial issues. Original articles that address any aspect of brachytherapy are invited. Letters to the Editor-in-Chief are encouraged.